Drug Profile
KUR 212
Alternative Names: I-020502; KUR-212Latest Information Update: 25 Feb 2016
Price :
$50
*
At a glance
- Originator Kuros Biosurgery
- Developer Kuros Biosciences
- Class Blood proteins; Growth factors; Peptides
- Mechanism of Action Platelet derived growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Burns
Most Recent Events
- 21 Aug 2015 Phase-II development is ongoing in Germany